186 related articles for article (PubMed ID: 25405143)
1. Comparison of the efficacy of methotrexate and actinomycin D in the treatment of patients with stage I low risk gestational trophoblastic neoplasia (GTN).
Shahbazian N; Razi T; Razi S; Yazdanpanah L
Med J Islam Repub Iran; 2014; 28():78. PubMed ID: 25405143
[TBL] [Abstract][Full Text] [Related]
2. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
[TBL] [Abstract][Full Text] [Related]
3. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
[TBL] [Abstract][Full Text] [Related]
4. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
[TBL] [Abstract][Full Text] [Related]
5. Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0-4): study protocol for a prospective, multicentre, randomized trial.
Jiang F; Mao MY; Xiang Y; Lu X; Guan CL; Jiao LZ; Wan XR; Feng FZ; Ren T; Yang JJ; Zhao J
BMC Cancer; 2023 Aug; 23(1):784. PubMed ID: 37612621
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
[TBL] [Abstract][Full Text] [Related]
7. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial.
Lertkhachonsuk AA; Israngura N; Wilailak S; Tangtrakul S
Int J Gynecol Cancer; 2009 Jul; 19(5):985-8. PubMed ID: 19574798
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
9. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease.
Lee YJ; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2017 Mar; 28(2):e8. PubMed ID: 27819410
[TBL] [Abstract][Full Text] [Related]
10. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
[TBL] [Abstract][Full Text] [Related]
12. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
13. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
[TBL] [Abstract][Full Text] [Related]
14. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
[TBL] [Abstract][Full Text] [Related]
16. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
17. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
18. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
[TBL] [Abstract][Full Text] [Related]
19. Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia.
Aminimoghaddam S; Nezhadisalami F; Anjidani S; Barzin Tond S
Med J Islam Repub Iran; 2018; 32():36. PubMed ID: 30159287
[No Abstract] [Full Text] [Related]
20. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
